Significant Patient Journey Data Links Clinical Outcomes to Real-World Effects, Tackling Essential Evidence Shortcomings in Various Medical Fields
MONTREAL, May 14, 2025–(BUSINESS WIRE)–Komodo Health has announced that its healthcare intelligence platform facilitated 31 research presentations at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. This impressive collection includes three studies conducted by Komodo’s own researchers and 27 collaborative projects involving academic institutions, life sciences companies, and healthcare organizations. “The sheer volume and variety of research supported by our healthcare insights highlight the increasing need for high-quality real-world data coupled with sophisticated analytical tools,” stated Arif Nathoo, MD, CEO and Co-Founder of Komodo Health. “By linking individual patient experiences to broader health outcomes, we’re empowering researchers to discover actionable insights that can enhance clinical practices, healthcare policies, and patient results.”
Highlighting the Value of Komodo’s Real-World Evidence Across Therapeutic Areas
The research presentations at ISPOR 2025 illustrate the significance of Komodo’s real-world evidence across numerous therapeutic domains, including: In Oncology, Salix Pharmaceuticals, Analysis Group, and Bausch Health explored the economic impact of opioid-induced constipation in patients both with and without cancer; In Cardiovascular health, Veradigm investigated the discrepancies between apolipoprotein B and low-density lipoprotein cholesterol levels in predicting hypertension risk, assessing how this relates to different hypertension development patterns in diabetic and non-diabetic groups; In Metabolic disorders, Novo Nordisk focused on non-invasive diagnostic techniques and earlier intervention strategies for metabolic dysfunction-associated steatohepatitis (MASH); In Neurology, Jazz Pharmaceuticals evaluated healthcare resource use and costs for individuals with narcolepsy or idiopathic hypersomnia (IH), who may be at higher risk for adverse clinical outcomes linked to sodium due to existing cardiovascular, cardiometabolic, or renal conditions; Lastly, in the Rare disease category, Chiesi examined medical claims data to gain insights into healthcare resource utilization for patients suffering from Fabry disease. Additionally, three poster presentations from Komodo researchers featured methodological innovations: Sequential target trial emulation to evaluate the mortality impact of treatments for amyotrophic lateral sclerosis (CO79); Benchmarking the duration of injectable medications through claims intervals versus days’ supply analysis (SA31); and Expanding longitudinal patient data via tokenized linkage technology (RWD134).
Enhancing Research Through Integrated Data Analytics
Komodo offers a comprehensive perspective of over 330 million patient journeys by integrating de-identified claims data with specialty datasets, including laboratory results, genomic information, and demographic statistics. This integration addresses significant challenges faced in health economics and outcomes research (HEOR). Traditionally, HEOR teams have had to rely on fragmented and incomplete datasets that only provide limited snapshots of patients’ healthcare experiences within networks. However, Komodo’s platform allows researchers to connect various datasets without the lengthy data cleaning and integration processes that usually take months. The capacity to deepen disease understanding at the individual patient level—by incorporating lab data, electronic health records, insurance details, and demographics like race and ethnicity—enables teams to independently assess cohort feasibility and insights. This capability significantly shortens study planning timelines and yields more precise estimates of treatment patterns, healthcare resource utilization, and costs. “By bridging crucial data voids and adopting a patient-focused approach to HEOR, our robust, all-in-one platform combines clean, interconnected, and compliant real-world data,” Nathoo emphasized. “We eliminate the complications of messy integrations, manual data management, and the need to build cohorts from the ground up, allowing HEOR teams to produce evidence more quickly. The inclusion of demographic insights, such as race and ethnicity, at a near-complete level enables researchers to better analyze the clinical and financial impacts of new therapies across diverse populations, recognizing that disease burden is not evenly distributed among demographic groups.”
About Komodo Health
Komodo Health is a technology and healthcare insights firm dedicated to providing the Evidentiary Standard for real-world data and analytics. By combining the most comprehensive and unbiased view of patient encounters with AI-enhanced, purpose-built software, Komodo connects patient journeys with large-scale health outcomes. Serving stakeholders in Life Sciences, payers, providers, and developers, Komodo empowers its clients to efficiently obtain patient-centric insights at scale, facilitating quicker decision-making, optimizing workflows, addressing care gaps, and alleviating the burden of disease. For additional information, please visit Komodohealth.com.
